Savage Brian sold 2,525 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD at $39.15 for −$98.8k on Sep 18, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Interim Chief Legal Officer
Interim Chief Legal Officer
Filed Sep 22, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$98,841.13Shares × reported price
Shares traded
2,525Ordinary Shares
Price per share
$39.15Reported price. Read footnotes for ranges.
% of reported position traded
22.27%This security and ownership context
Holdings after
8,814Direct
Trade date
Sep 18, 2026Sell
Filed
Sep 22, 2026, 5:01 PM ET4-day reporting delay
Accession
0001193125-26-398105Code S · Transaction 227733
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 11,339 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 18, 2026Option exercise4,503$34.70$156,254.10Trade 227731
Sep 18, 2026Sell4,503$38.69−$174,221.07Trade 227732
Sep 18, 2026Sell314$38.70−$12,152.99Trade 227734
Sep 18, 2026Option exercise4,503$34.70−$156,254.10Trade 227735
5 transaction rows in this filing. Joint filers share the same rows.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −4.4%1w ago −5.4%1d ago 0%
Returns since7d +1.6%30d +3.6%90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $39.155, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.